Nimenrix vaccine being distributed by Vivian Corporation
e-info Archive
Vivian Corporation, together with Pfizer, believe in the promise and value of vaccine in improving people’s life. Following Pfizer’s acquisition of Nimenrix from GSK, Vivian Corporation is now the sole distributor responsible for this important addition to the meningitis vaccine portfolio.
Nimenrix is indicated for active immunisation of individuals from the age of 12 months and above against invasive meningococcal diseases caused by Neisseria meningitidis group A, C, W-135 and Y.
The other vaccines in Vivian’s vaccine portfolio include Neisvac-C and Prevenar 13.
Kenneth Briffa
Medical Representative – Healthcare
Vivian CORPORATION
Celebrating Life since 1952
T: +356 2258 8637 M: +356 99404304
Please login to access this information.
Tags
adoloscence
cancer
cannabis
Cardiology
Contributions
covid 19
dementia
Dermatology
Dermfest
Diabetes
Editorial
endocrinology
environmental health
exercise
Family Medicine
Francesco Carelli
gastroenterology
Geriatrics
gynaecology
hypertension
Infectious Diseases
Medical Education
Medical Ethics
Medicine and the arts
microbionta
Neurology
Nutrition
obesity
obstetrics
Oncology
Orthopaedics
Paediatrics
Pharmacology
Pharmacy Practice
pregnancy
Psychiatry
Public Health
Radiology
Respiratory Medicine
Rheumatology
smoking
Surgery
TheSynapse Interview
Urology
Women's health